These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11419023)

  • 21. A bioluminescence imaging based in vivo model for preclinical testing of novel cellular immunotherapy strategies to improve the graft-versus-myeloma effect.
    Rozemuller H; van der Spek E; Bogers-Boer LH; Zwart MC; Verweij V; Emmelot M; Groen RW; Spaapen R; Bloem AC; Lokhorst HM; Mutis T; Martens AC
    Haematologica; 2008 Jul; 93(7):1049-57. PubMed ID: 18492693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting.
    Galimberti S; Benedetti E; Morabito F; Fazzi R; Pacini S; Andreazzoli F; Martino M; Iacopino P; Petrini M
    Transpl Immunol; 2005 Dec; 15(2):173-7. PubMed ID: 16412962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving transplant options for multiple myeloma: autologous and nonmyeloablative allogenic.
    Gibson J; Ho PJ; Joshua D
    Transplant Proc; 2004 Oct; 36(8):2501-3. PubMed ID: 15561295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of stem cell transplantation.
    Harousseau JL
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor antigen immunization of sibling stem cell transplant donors in multiple myeloma.
    Neelapu SS; Munshi NC; Jagannath S; Watson TM; Pennington R; Reynolds C; Barlogie B; Kwak LW
    Bone Marrow Transplant; 2005 Aug; 36(4):315-23. PubMed ID: 15968284
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcome of unrelated transplants in patients with multiple myeloma.
    Ballen KK; King R; Carston M; Kollman C; Nelson G; Lim S; Reece D; Giralt S; Vesole DH
    Bone Marrow Transplant; 2005 Apr; 35(7):675-81. PubMed ID: 15723085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Allogeneic transplantation for multiple myeloma: late relapse may occur as localised lytic lesion/plasmacytoma despite ongoing molecular remission.
    Byrne JL; Fairbairn J; Davy B; Carter IG; Bessell EM; Russell NH
    Bone Marrow Transplant; 2003 Feb; 31(3):157-61. PubMed ID: 12621475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
    Ayuk F; Perez-Simon JA; Shimoni A; Sureda A; Zabelina T; Schwerdtfeger R; Martino R; Sayer HG; Alegre A; Lahuerta JJ; Atanackovic D; Wolschke C; Nagler A; Zander AR; San Miguel JF; Kröger N
    Haematologica; 2008 Sep; 93(9):1343-50. PubMed ID: 18641030
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Physiopathology and possible clinical use of hematopoietic stem cells. Recent advances].
    Testa U
    Recenti Prog Med; 2009 Mar; 100(3):144-55. PubMed ID: 19475843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
    Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
    Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma.
    Giralt S; Aleman A; Anagnostopoulos A; Weber D; Khouri I; Anderlini P; Molldrem J; Ueno NT; Donato M; Korbling M; Gajewski J; Alexanian R; Champlin R
    Bone Marrow Transplant; 2002 Sep; 30(6):367-73. PubMed ID: 12235521
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Recent progress in hematopoietic stem cell transplantation].
    Shinagawa K
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):727-35. PubMed ID: 16770089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different gamma/delta T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation.
    Galimberti S; Benedetti E; Morabito F; Petrini I; Battolla B; Papineschi F; Fazzi R; Ciabatti E; Martino M; Cuzzola M; Console G; Iacopino P; Petrini M
    Leuk Res; 2006 May; 30(5):529-35. PubMed ID: 16249028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.
    Carella AM; Beltrami G; Corsetti MT; Scalzulli P; Carella AM; Musto P
    Haematologica; 2004 Dec; 89(12):1534-6. PubMed ID: 15590410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Allogeneic transplantation in multiple myeloma.
    Gahrton G; Björkstrand B
    Haematologica; 2008 Sep; 93(9):1295-300. PubMed ID: 18757850
    [No Abstract]   [Full Text] [Related]  

  • 37. [Intensive treatment of multiple myeloma].
    Harousseau JL
    Bull Acad Natl Med; 2003; 187(2):405-13; discussion 413-5. PubMed ID: 14556449
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of thalidomide therapy for extramedullary relapse of myeloma following allogeneic transplantation.
    Biagi JJ; Mileshkin L; Grigg AP; Westerman DW; Prince HM
    Bone Marrow Transplant; 2001 Dec; 28(12):1145-50. PubMed ID: 11803357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. OTI-010 Osiris Therapeutics/JCR Pharmaceuticals.
    Taupin P
    Curr Opin Investig Drugs; 2006 May; 7(5):473-81. PubMed ID: 16729725
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
    Kröger N; Einsele H; Wolff D; Casper J; Freund M; Derigs G; Wandt H; Schäfer-Eckart K; Wittkowsky G; Schmitz N; Krüger W; Zabelina T; Renges H; Ayuk F; Krüll A; Zander A;
    Bone Marrow Transplant; 2003 Jun; 31(11):973-9. PubMed ID: 12774047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.